Dr. med. Dr. nat. med. Jan Rybniker - Curriculum Vitae

Education and professional career

2017: Comprehensive host cell-based antituberculous drug discovery – a novel approach to fight drug resistant tuberculosis Fach Innere Medizin
since 2016: Independent Research Group Leader, Center for Molecular Medicine Cologne (ZMMK), Head ZMMK BSL3-TB facility
since 2015: Board exam Internal Medicine Jan. 2016
2011 - 2015: Postdoctoral fellow at the laboratory of Prof. Stewart Cole, Dept. of Life Sciences - EPFL, Switzerland
2007 - 2011: MD-PhD thesis“Identification and Characterization of Host Shut-Off Proteins of Mycobacteriophages” summa cum laude (with distinction) at the Center for Molecular Medicine Cologne, Germany
2007 - 2010: MD-PhD candidate, center for molecular medicine, University of Cologne, Germany
2006 - 2011: Resident at the 1st Dept. of Internal Medicine, University of Cologne, Germany
2004 - 2006: Resident at the Bernhard-Nocht-Institute for Tropcial Medicine, Hamburg, Germany
2000 - 2004: MD thesis“Transposon mutagenesis of Mycobacterium ulcerans and Mycobacterium marinum using temperature- sensitive mycobacteriophages “ summa cum laude
- At the Institute for medical Microbiology, Immunology and Hygiene (Univ. of Cologne)
- At the Prince Leopold Institute of Tropical Medicine, Antwerp, Institute scientifique de la Santé, Brussels

Selected publications

Suarez I, Lehmann C, Gruell H, Graeb J, Kochanek M, Fatkenheuer G, Plum G, van Wengen A, van de Vosse E, Hartmann P, Hanitsch LG, Rybniker J. Repurposing QuantiFERON for detection of neutralizing IFN-gamma autoantibodies in patients with nontuberculous mycobacterial infections. Clin Infect Dis. 2017.

Herrmann J*, Rybniker J*, Muller R. Novel and revisited approaches in antituberculosis drug discovery. Curr Opin Biotechnol. 2017; 48: 94-101.
(*shared first authorship)

Suarez I, Roderus L, van Gumpel E, Jung N, Lehmann C, Fatkenheuer G, Hartmann P, Plum G, Rybniker J. Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort. Infection. 2017.

Lou Y, Rybniker J, Sala C, Cole ST. EspC forms a filamentous structure in the cell envelope of Mycobacterium tuberculosis and impacts ESX-1 secretion. Mol Microbiol. 2017; 103(1): 26-38.

Godel P, Fischer J, Scheid C, Gathof BS, Wolf J, Rybniker J. Familial acquired thrombotic thrombocytopenic purpura in siblings - no immunogenetic link with associated human leucocyte antigens. Eur J Haematol. 2017; 98(3): 311-3.

Singh V, Dhar N, Pato J, Kolly GS, Kordulakova J, Forbak M, Evans JC, Szekely R, Rybniker J, Palcekova Z, Zemanova J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Ainsa JA, Warner DF, Keri G, Mikusova K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC. Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. Mol Microbiol. 2017; 103(1): 13-25.

Foo CS, Lechartier B, Kolly GS, Boy-Rottger S, Neres J, Rybniker J, Lupien A, Sala C, Piton J, Cole ST. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016; 60(11): 6451-9.

Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill MJ, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodriguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Perez-Hoyos S, Jarrin I, Guest JL, Monforte AD, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernan MA. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 2015.

Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nature Commun. 2015; 6: 7659.

1Wassermann R, Gulen MF, Sala C, Perin SG, Lou Y, Rybniker J, Schmid-Burgk JL, Schmidt T, Hornung V, Cole ST, Ablasser A. Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-Dependent Intracellular Immune Responses through ESX-1. Cell Host Microbe. 2015; 17(6): 799-810.

Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Rottger S, Zhang M, Szekely R, Greff Z, Orfi L, Szabadkai I, Pato J, Keri G, Cole ST. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe. 2014; 16(4): 538-48.

Zhang M, Chen JM, Sala C, Rybniker J, Dhar N, Cole ST. EspI regulates the ESX-1 secretion system in response to ATP levels in Mycobacterium tuberculosis. Mol Microbiol. 2014; 93(5): 1057-65.

Rybniker J, Pojer F, Marienhagen J, Kolly GS, Chen JM, van Gumpel E, Hartmann P, Cole ST. The cysteine desulfurase IscS of Mycobacterium tuberculosis is involved in iron-sulfur cluster biogenesis and oxidative stress defence. Biochem J. 2014; 459(3): 467-78.

Lechartier B, Rybniker J, Zumla A, Cole ST. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med. 2014; 6(2): 158-68.

Chen JM, Zhang M, Rybniker J, Basterra L, Dhar N, Tischler AD, Pojer F, Cole ST. Phenotypic profiling of Mycobacterium tuberculosis EspA point mutants reveals that blockage of ESAT-6 and CFP-10 secretion in vitro does not always correlate with attenuation of virulence. J Bacteriol. 2013; 195(24): 5421-30.

Chen JM, Zhang M, Rybniker J, Boy-Rottger S, Dhar N, Pojer F, Cole ST. Mycobacterium tuberculosis EspB binds phospholipids and mediates EsxA-independent virulence. Mol Microbiol. 2013; 89(6): 1154-66.

Rybniker J, Nowag A, Janicki H, Demant K, Hartmann P, Buning H. Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines. J Virol. 2012; 86(24): 13800-4.